Recommendations for optimizing methotrexate treatment for patients with rheumatoid arthritis

References

• ChanESCronsteinBNMolecular action of methotrexate in inflammatory diseasesArthritis Res20024426627312106498
   PubMedGoogle Scholar
• SinghJASaagKGBridgesSLJr2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritisArthritis Rheumatol2016681126
   PubMed Web of Science ®Google Scholar
• SmolenJSLandewéRBreedveldFCEULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 updateAnn Rheum Dis201473349250924161836
   PubMed Web of Science ®Google Scholar
• TodoertiMMaglioneWBerneroESystematic review of 2008–2012 literature and update of recommendations for the use of methotrexate in rheumatic diseases, with a focus on rheumatoid arthritisReumatismo201365520721824399184
   PubMedGoogle Scholar
• RauRHerbornGBenefit and risk of methotrexate treatment in rheumatoid arthritisClin Exp Rheumatol2004225 suppl 35S83S9415552520
   PubMed Web of Science ®Google Scholar
• VerstappenSMLuntMBunnDKScottDGSymmonsDPIn patients with early inflammatory polyarthritis, ACPA positivity, younger age and inefficacy of the first non-biological DMARD are predictors for receiving biological therapy: results from the Norfolk Arthritis RegisterAnn Rheum Dis20117081428143221551505
   PubMed Web of Science ®Google Scholar
• DavisJM3rdKnutsonKLSkinnerJAA profile of immune response to herpesvirus is associated with radiographic joint damage in rheumatoid arthritisArthritis Res Ther2012141R2422293286
   PubMed Web of Science ®Google Scholar
• DrouinJHaraouiB3e Initiative GroupPredictors of clinical response and radiographic progression in patients with rheumatoid arthritis treated with methotrexate monotherapyJ Rheumatol20103771405141020436076
   PubMed Web of Science ®Google Scholar
• ShiozawaKYamaneTMurataMMMP-3 as a predictor for structural remission in RA patients treated with MTX monotherapyArthritis Res Ther2016185526922083
   PubMed Web of Science ®Google Scholar
• SokkaTIncreases in use of methotrexate since the 1980sClin Exp Rheumatol2010285 suppl 61S13S20
   Web of Science ®Google Scholar
• PincusTGibsonKACastrejónIUpdate on methotrexate as the anchor drug for rheumatoid arthritisBull Hosp Jt Dis201371Suppl 1S9S19
   Google Scholar
• RohrMKMikulsTRCohenSBThorneCJO’DellJRThe underuse of methotrexate in the treatment of RA: a national analysis of prescribing practices in the U.S.Arthritis Care Res (Hoboken) Epub20161118
   Web of Science ®Google Scholar
• YaziciYShiNJohnAUtilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16,752 newly diagnosed patients and patients new to biologic therapyBull NYU Hosp Jt Dis2008662778518537774
   PubMedGoogle Scholar
• CurtisJRZhangJXieFUse of oral and subcutaneous methotrexate in rheumatoid arthritis patients in the United StatesArthritis Care Res (Hoboken)201466111604161124942466
   PubMed Web of Science ®Google Scholar
• DetertJKlausPBiologic monotherapy in the treatment of rheumatoid arthritisBiologics20159354326028960
   PubMedGoogle Scholar
• O’DellJRCohenSBThorneJCMikulsTRChanging use of methotrexate (MTX) and biologics in the treatment of rheumatoid arthritis (RA) in the United States (US): results of a comprehensive pharmaceutical claims analysisPresented at: EULAR/Annual European Congress of RheumatologyJune 8–11; 2016London
   Google Scholar
• DesaiRJSolomonDHLiuJKimSC webpage on the InternetSecular trends in use of disease modifying anti-rheumatic drugs for the treatment of rheumatoid arthritis in the United States [abstract]Arthritis Rheumatol201567suppl 10 Available from: http://acrabstracts.org/abstract/secular-trends-in-use-of-disease-modifying-anti-rheumatic-drugs-for-the-treatment-of-rheumatoid-arthritis-in-the-united-statesAccessed October 24, 2016
   Google Scholar
• Engel-NitzNMOgaleSKulakodluMUse of anti-tumor necrosis factor therapy: a retrospective study of monotherapy and adherence to combination therapy with non-biologic disease-modifying anti-rheumatic drugsRheumatol Ther20152212713927747532
   PubMedGoogle Scholar
• DesaiRJRaoJKHansenRAFangGMaciejewskiMLFarleyJFPredictors of treatment initiation with tumor necrosis factor-a inhibitors in patients with rheumatoid arthritisJ Manag Care Spec Pharm201420111110112025351972
   PubMed Web of Science ®Google Scholar
• ZhangJXieFDelzellETrends in the use of biologic agents among rheumatoid arthritis patients enrolled in the US medicare programArthritis Care Res (Hoboken)201365111743175123754804
   PubMedGoogle Scholar
• ManaraMBianchiGBruschiEAdherence to current recommendations on the use of methotrexate in rheumatoid arthritis in Italy: results from the MARI studyClin Exp Rheumatol201634347347927050478
   PubMed Web of Science ®Google Scholar
• IdolazziLAdamiSCapozzaRSuboptimal methotrexate use in rheumatoid arthritis patients in Italy: the MARI studyClin Exp Rheumatol201533689589926690890
   PubMed Web of Science ®Google Scholar
• TianHCronsteinBNUnderstanding the mechanisms of action of methotrexate: implications for the treatment of rheumatoid arthritisBull NYU Hosp Jt Dis200765316817317922664
   PubMedGoogle Scholar
• MilneGRPalmerTMAnti-inflammatory and immunosuppressive effects of the A2A adenosine receptorScientificWorldJournal20111132033921298223
   PubMed Web of Science ®Google Scholar
• EmeryPSebbaAHuizingaTWBiologic and oral disease-modifying antirheumatic drug monotherapy in rheumatoid arthritisAnn Rheum Dis201372121897190423918035
   PubMed Web of Science ®Google Scholar
• TaylorPvan VollenhovenRAletahaDOptimising patient outcomes throughout the rheumatoid arthritis patient journey: the exception, the standard, and the ruleEMJ Rheumatol201633647
   Google Scholar
• Lopez-OlivoMASiddhanamathaHRSheaBTugwellPWellsGASuarez-AlmazorMEMethotrexate for treating rheumatoid arthritisCochrane Database Syst Rev20146CD000957
   PubMed Web of Science ®Google Scholar
• HazlewoodGSBarnabeCTomlinsonGMarshallDDevoeDBombardierCMethotrexate monotherapy and methotrexate combination therapy with traditional and biologic disease modifying antirheumatic drugs for rheumatoid arthritis: abridged Cochrane Systematic Review and network meta-analysisBMJ2016353i177727102806
   PubMed Web of Science ®Google Scholar
• KlareskogLvan der HeijdeDde JagerJPTherapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trialLancet2004363941067568115001324
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKlareskogLRodriguez-ValverdeVComparison of etanercept and methotrexate, alone and combined, in the treatment of rheumatoid arthritis: two-year clinical and radiographic results from the TEMPO study, a double-blind, randomized trialArthritis Rheum20065441063107416572441
   PubMed Web of Science ®Google Scholar
• van der HeijdeDKlareskogLLandewéRDisease remission and sustained halting of radiographic progression with combination etanercept and methotrexate in patients with rheumatoid arthritisArthritis Rheum200756123928393918050208
   PubMed Web of Science ®Google Scholar
• MorelandLWO’DellJRPaulusHEA randomized comparative effectiveness study of oral triple therapy versus etanercept plus methotrexate in early aggressive rheumatoid arthritis: the treatment of Early Aggressive Rheumatoid Arthritis TrialArthritis Rheum20126492824283522508468
   PubMed Web of Science ®Google Scholar
• O’DellJRCurtisJRMikulsTRValidation of the methotrexate-first strategy in patients with early, poor-prognosis rheumatoid arthritis: results from a two-year randomized, double-blind trialArthritis Rheum20136581985199423686414
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFErnestamSGeborekPAddition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in patients with early rheumatoid arthritis (Swefot trial): 1-year results of a randomised trialLancet2009374968845946619665644
   PubMed Web of Science ®Google Scholar
• van VollenhovenRFGeborekPForslindKConventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trialLancet201237998271712172022464340
   PubMed Web of Science ®Google Scholar
• PincusTFurerVSokkaTUnderestimation of the efficacy, effectiveness, tolerability, and safety of weekly low-dose methotrexate in information presented to physicians and patientsClin Exp Rheumatol2010285 suppl 61S68S7921044437
   PubMed Web of Science ®Google Scholar
• DuránJBockornyMDalalDLaValleyMFelsonDTMethotrexate dosage as a source of bias in biological trials in rheumatoid arthritis: a systematic reviewAnn Rheum Dis20167591595159827091836
   PubMed Web of Science ®Google Scholar
• YamanakaHIshiguroNTakeuchiTRecovery of clinical but not radiographic outcomes by the delayed addition of adalimumab to methotrexate-treated Japanese patients with early rheumatoid arthritis: 52-week results of the HOPEFUL-1 trialRheumatology (Oxford)201453590491324441150
   PubMed Web of Science ®Google Scholar
• WaskoMCDasguptaAHubertHFriesJFWardMMPropensity-adjusted association of methotrexate with overall survival in rheumatoid arthritisArthritis Rheum201365233434223044791
   PubMed Web of Science ®Google Scholar
• Tornero MolinaJBallina GarcíaFJCalvo AlénJRecommendations for the use of methotrexate in rheumatoid arthritis: up and down scaling of the dose and administration routesReumatol Clin20151113824746914
   PubMedGoogle Scholar
• VisserKvan der HeijdeDOptimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literatureAnn Rheum Dis20096871094109919033290
   PubMed Web of Science ®Google Scholar
• NairSCJacobsJWBakkerMFDetermining the lowest optimally effective methotrexate dose for individual RA patients using their dose response relation in a tight control treatment approachPLoS One2016113e014879126987073
   PubMed Web of Science ®Google Scholar
• HermanRAVeng-PedersenPHoffmanJKoehnkeRFurstDEPharmacokinetics of low-dose methotrexate in rheumatoid arthritis patientsJ Pharm Sci19897821651712715941
   PubMed Web of Science ®Google Scholar
• YeeSWGongLBadagnaniIGiacominiKMKleinTEAltmanRBSLC19A1 pharmacogenomics summaryPharmacogenet Genomics2010201170871520811316
   PubMed Web of Science ®Google Scholar
• LaverdièreCChiassonSCosteaIMoghrabiAKrajinovicMPolymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemiaBlood2002100103832383412411325
   PubMed Web of Science ®Google Scholar
• SheaBSwindenMVTanjong GhogomuEFolic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritisCochrane Database Syst Rev20135CD000951
   PubMed Web of Science ®Google Scholar
• WhittleSLHughesRAFolate supplementation and methotrexate treatment in rheumatoid arthritis: a reviewRheumatology (Oxford)200443326727114963199
   PubMed Web of Science ®Google Scholar
• GriffithSMFisherJClarkeSDo patients with rheumatoid arthritis established on methotrexate and folic acid 5 mg daily need to continue folic acid supplements long term?Rheumatology (Oxford)200039101102110911035130
   PubMed Web of Science ®Google Scholar
• MedleySDolanALCoakleyGHow safe is starting high dose methotrexate?Presented at EULAR/Annual European Congress of RheumatologyJune 10–13, 2009Copenhagen Denmark Abstract SAT0150
   Google Scholar
• LampropoulosCEOrfanosPBourniaVKAdverse events and infections in patients with rheumatoid arthritis treated with conventional drugs or biologic agents: a real world studyClin Exp Rheumatol201533221622425664400
   PubMed Web of Science ®Google Scholar
• HoblELMaderRMJilmaBA randomized, double-blind, parallel, single-site pilot trial to compare two different starting doses of methotrexate in methotrexate-naïve adult patients with rheumatoid arthritisClin Ther20123451195120322516039
   PubMed Web of Science ®Google Scholar
• RupertoNMurrayKJGerloniVA randomized trial of parenteral methotrexate comparing an intermediate dose with a higher dose in children with juvenile idiopathic arthritis who failed to respond to standard doses of methotrexateArthritis Rheum20045072191220115248217
   PubMed Web of Science ®Google Scholar
• RingoldSWeissPFColbertRAChildhood Arthritis and Rheumatology Research Alliance consensus treatment plans for new-onset polyarticular juvenile idiopathic arthritisArthritis Care Res (Hoboken)20146671063107224339215
   PubMed Web of Science ®Google Scholar
• SoubrierMPuéchalXSibiliaJEvaluation of two strategies (initial methotrexate monotherapy vs its combination with adalimumab) in management of early active rheumatoid arthritis: data from the GUEPARD trialRheumatology (Oxford)200948111429143419741011
   PubMed Web of Science ®Google Scholar
• BykerkVPAkhavanPHazlewoodGSCanadian Rheumatology Association recommendations for pharmacological management of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugsJ Rheumatol20123981559158221921096
   PubMed Web of Science ®Google Scholar
• HameedBJonesHSubcutaneous methotrexate is well tolerated and superior to oral methotrexate in the treatment of rheumatoid arthritisInt J Rheum Dis2010134e83e8421199461
   PubMed Web of Science ®Google Scholar
• BianchiGCaporaliRTodoertiMMattanaPMethotrexate and rheumatoid arthritis: current evidence regarding subcutaneous versus oral routes of administrationAdv Ther201633336937826846283
   PubMed Web of Science ®Google Scholar
• BrancoJCBarcelosAde AraújoFPUtilization of subcutaneous methotrexate in rheumatoid arthritis patients after failure or intolerance to oral methotrexate: a Multicenter Cohort StudyAdv Ther2016331465726724937
   PubMed Web of Science ®Google Scholar
• PichlmeierUHeuerKUSubcutaneous administration of methotrexate with a prefilled autoinjector pen results in a higher relative bioavailability compared with oral administration of methotrexateClin Exp Rheumatol201432456357124983446
   PubMed Web of Science ®Google Scholar
• DervieuxTZablockiRKremerJRed blood cell methotrexate polyglutamates emerge as a function of dosage intensity and route of administration during pulse methotrexate therapy in rheumatoid arthritisRheumatology (Oxford)201049122337234520713496
   PubMed Web of Science ®Google Scholar
• HornungNEllingsenTAttermannJStengaard-PedersenKPoulsenJHPatients with rheumatoid arthritis treated with methotrexate (MTX): concentrations of steady-state erythrocyte MTX correlate to plasma concentrations and clinical efficacyJ Rheumatol20083591709171518634162
   PubMed Web of Science ®Google Scholar
• DervieuxTFurstDLeinDOPolyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritisArthritis Rheum20045092766277415457444
   PubMed Web of Science ®Google Scholar
• YadlapatiSEfthimiouPInadequate response or intolerability to oral methotrexate: is it optimal to switch to subcutaneous methotrexate prior to considering therapy with biologics?Rheumatol Int201636562763326936262
   PubMed Web of Science ®Google Scholar
• O’DellJRMikulsTRTaylorTHTherapies for active rheumatoid arthritis after methotrexate failureN Engl J Med2013369430731823755969
   PubMed Web of Science ®Google Scholar
• KatchamartWTrudeauJPhumethumVBombardierCMethotrexate monotherapy versus methotrexate combination therapy with non-biologic disease modifying anti-rheumatic drugs for rheumatoid arthritisCochrane Database Syst Rev20104CD008495
   Google Scholar
• KarlssonJANeoviusMNilssonJÅAddition of infliximab compared with addition of sulfasalazine and hydroxychloroquine to methotrexate in early rheumatoid arthritis: 2-year quality-of-life results of the randomised, controlled, SWEFOT trialAnn Rheum Dis201372121927193323196701
   PubMed Web of Science ®Google Scholar
• BuckleyFFinckhAHuizingaTWDejonckheereFJansenJPComparative efficacy of novel DMARDs as monotherapy and in combination with methotrexate in rheumatoid arthritis patients with inadequate response to conventional DMARDs: a network meta-analysisJ Manag Care Spec Pharm20152140942325943002
   PubMedGoogle Scholar
• OrmeMEMacgilchristKSMitchellSSpurdenDBirdASystematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70Biologics2012642946423269860
   PubMedGoogle Scholar
• FleischmannRKoenigASSzumskiANabHWMarshallLBananisEShort-term efficacy of etanercept plus methotrexate vs combinations of disease-modifying anti-rheumatic drugs with methotrexate in established rheumatoid arthritisRheumatology (Oxford)201453111984199324907147
   PubMed Web of Science ®Google Scholar
• SinghJAHossainATanjong GhogomuEMudanoASTugwellPWellsGABiologic or tofacitinib monotherapy for rheumatoid arthritis in people with traditional disease-modifying anti-rheumatic drug (DMARD) failure: a Cochrane Systematic Review and network meta-analysis (NMA)Cochrane Database Syst Rev201611CD01243727855242
   PubMedGoogle Scholar
• BerhanAEfficacy, safety and tolerability of tofacitinib in patients with an inadequate response to disease modifying anti-rheumatic drugs: a meta-analysis of randomized double-blind controlled studiesBMC Musculoskelet Disord20131433224279308
   PubMed Web of Science ®Google Scholar
• KremerJMBloomBJBreedveldFCThe safety and efficacy of a JAK inhibitor in patients with active rheumatoid arthritis: results of a double-blind, placebo-controlled phase IIa trial of three dosage levels of CP-690,550 versus placeboArthritis Rheum20096071895190519565475
   PubMed Web of Science ®Google Scholar
• ZerbiniCRadominskiSCardielMH webpage on the InternetEfficacy and safety of tofacitinib monotherapy versus combination therapy in a Latin American subpopulation of patients with rheumatoid arthritis: a pooled phase 3 analysis [abstract]Arthritis Rheumatol201567suppl 10 Available from: http://acrabstracts.org/abstract/efficacy-and-safety-of-tofacitinib-monotherapy-versus-combination-therapy-in-a-latin-american-subpopulation-of-patients-with-rheumatoid-arthritis-a-pooled-phase-3-analysisAccessed October 24, 2016
   Google Scholar
• NikiphorouENegoescuAFitzpatrickJDIndispensable or intolerable? Methotrexate in patients with rheumatoid and psoriatic arthritis: a retrospective review of discontinuation rates from a large UK cohortClin Rheumatol201433560961424609758
   PubMed Web of Science ®Google Scholar
• LiDYangZKangPXieXSubcutaneous administration of methotrexate at high doses makes a better performance in the treatment of rheumatoid arthritis compared with oral administration of methotrexate: a systematic review and meta-analysisSemin Arthritis Rheum201645665666226686022
   PubMed Web of Science ®Google Scholar
• KromannCBLage-HansenPRKoefoedMJemecGBDoes switching from oral to subcutaneous administration of methotrexate influence on patient reported gastro-intestinal adverse effects?J Dermatolog Treat201526218819024852821
   PubMed Web of Science ®Google Scholar
• VerstappenSMBakkerMFHeurkensAHAdverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA studyAnn Rheum Dis20106961044104819581281
   PubMed Web of Science ®Google Scholar
• FurstDEKoehnkeRBurmeisterLFKohlerJCargillIIncreasing methotrexate effect with increasing dose in the treatment of resistant rheumatoid arthritisJ Rheumatol19891633133202724250
   PubMed Web of Science ®Google Scholar
• TishlerMCaspiDYaronMMethotrexate treatment of rheumatoid arthritis: is a fortnightly maintenance schedule enough?Ann Rheum Dis19925112133013311485816
   PubMed Web of Science ®Google Scholar
• LuisMPacheco-TenaCCazarín-BarrientosJComparison of two schedules for administering oral low-dose methotrexate (weekly versus every-other-week) in patients with rheumatoid arthritis in remission: a twenty-four week, single blind, randomized studyArthritis Rheum199942102160216510524688
   PubMed Web of Science ®Google Scholar
• KremerJMDaviesJMRynesRIEvery-other-week methotrexate in patients with rheumatoid arthritis. A double-blind, placebo-controlled prospective studyArthritis Rheum19953856016077748214
   PubMed Web of Science ®Google Scholar
• KremerJMRynesRIBartholomewLESevere flare of rheumatoid arthritis after discontinuation of long-term methotrexate therapy. Double-blind studyAm J Med19878247817863551606
   PubMed Web of Science ®Google Scholar
• GøtzschePCHansenMStoltenbergMRandomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritisScand J Rheumatol19962541941998792795
   PubMed Web of Science ®Google Scholar
• ten WoldeSBreedveldFCHermansJRandomised placebo-controlled study of stopping second-line drugs in rheumatoid arthritisLancet199634789983473528598699
   PubMed Web of Science ®Google Scholar
• HiderSLSilmanABunnDManningSSymmonsDLuntMComparing the long-term clinical outcome of treatment with methotrexate or sulfasalazine prescribed as the first disease-modifying antirheumatic drug in patients with inflammatory polyarthritisAnn Rheum Dis200665111449145516540547
   PubMed Web of Science ®Google Scholar
• AlamMKSutradharSRPanditHComparative study on methotrexate and hydroxychloroquine in the treatment of rheumatoid arthritisMymensingh Med J201221339139822828532
   PubMedGoogle Scholar
• CohenSCannonGWSchiffMTwo-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator GroupArthritis Rheum20014491984199211592358
   PubMed Web of Science ®Google Scholar
• TugwellPWellsGStrandVClinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Leflunomide Rheumatoid Arthritis Investigators GroupArthritis Rheum200043350651410728742
   PubMed Web of Science ®Google Scholar
• BurmesterGRKivitzAJKupperHEfficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomised CONCERTO trialAnn Rheum Dis20157461037104424550168
   PubMed Web of Science ®Google Scholar
• BurmesterGRKivitzAJVan VollenhovenRFMethotrexate dose has minimal effects on methotrexate-related toxicity in patients with early rheumatoid arthritis treated in combination with adalimumab – results of Concerto Trial. 2013Arthritis Rheum201365Suppl 102688
   Google Scholar
  Presented at American College of Rheumatology/Association of Rheumatology Health Professionals Annual MeetingSan Diego, CAOctober 25–30, 2013
   Google Scholar
• BykerkVPÖstörAJAlvaro-GraciaJComparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practiceClin Rheumatol201534356357125604316
   PubMed Web of Science ®Google Scholar
• DiBenedettiDBZhouXReynoldsMOgaleSBestJHAssessing methotrexate adherence in rheumatoid arthritis: a cross-sectional surveyRheumatol Ther201521738427747496
   PubMedGoogle Scholar
• GrijalvaCGChungCPArbogastPGSteinCMMitchelEFJrGriffinMRAssessment of adherence to and persistence on disease-modifying antirheumatic drugs (DMARDs) in patients with rheumatoid arthritisMed Care20074510 suppl 2S66S7617909386
   PubMed Web of Science ®Google Scholar
• HillJBirdHJohnsonSEffect of patient education on adherence to drug treatment for rheumatoid arthritis: a randomised controlled trialAnn Rheum Dis200160986987511502614
   PubMed Web of Science ®Google Scholar
• HomerDNightingalePJobanputraPProviding patients with information about disease-modifying anti-rheumatic drugs: individually or in groups? A pilot randomized controlled trial comparing adherence and satisfactionMusculoskeletal Care200972789218792423
   PubMedGoogle Scholar
• EversAWKraaimaatFWvan RielPLde JongAJTailored cognitive-behavioral therapy in early rheumatoid arthritis for patients at risk: a randomized controlled trialPain20021001–214115312435467
   PubMed Web of Science ®Google Scholar
• HazlewoodGSThorneJCPopeJEThe comparative effectiveness of oral versus subcutaneous methotrexate for the treatment of early rheumatoid arthritisAnn Rheum Dis20167561003100825979945
   PubMed Web of Science ®Google Scholar
• ScottDGClaydonPEllisCRetrospective evaluation of continuation rates following a switch to subcutaneous methotrexate in rheumatoid arthritis patients failing to respond to or tolerate oral methotrexate: the MENTOR studyScand J Rheumatol201443647047624898259
   PubMed Web of Science ®Google Scholar
• RavelliAMartiniAMethotrexate in juvenile idiopathic arthritis: answers and questionsJ Rheumatol20002781830183310955319
   PubMed Web of Science ®Google Scholar
• RamananAVWhitworthPBaildamEMUse of methotrexate in juvenile idiopathic arthritisArch Dis Child200388319720012598376
   PubMed Web of Science ®Google Scholar
• SchiffMHJaffeJSFreundlichBHead-to-head, randomised, crossover study of oral versus subcutaneous methotrexate in patients with rheumatoid arthritis: drug-exposure limitations of oral methotrexate at doses ≥15 mg may be overcome with subcutaneous administrationAnn Rheum Dis20147381549155124728329
   PubMed Web of Science ®Google Scholar
• HoekstraMHaagsmaCNeefCProostJKnuifAvan de LaarMBioavailability of higher dose methotrexate comparing oral and subcutaneous administration in patients with rheumatoid arthritisJ Rheumatol200431464564815088287
   PubMed Web of Science ®Google Scholar
• SchiffMSadowskiP webpage on the InternetOral to subcutaneous methotrexate dose-conversion strategies in the treatment of rheumatoid arthritis [abstract]Arthritis Rheumatol201567suppl 10 Available from: http://acrabstracts.org/abstract/oral-to-subcutaneous-metho-trexate-dose-conversion-strategies-in-the-treatment-of-rheumatoid-arthritisAccessed October 24, 2016
   Google Scholar
• LouderAMSinghASavernoKPatient preferences regarding rheumatoid arthritis therapies: a conjoint analysisAm Health Drug Benefits2016928493
   PubMed Web of Science ®Google Scholar
• BraunJKästnerPFlaxenbergPComparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: results of a six-month, multicenter, randomized, double-blind, controlled, phase IV trialArthritis Rheum2008581738118163521
   PubMed Web of Science ®Google Scholar
• GottheilSThorneJCSchieirOEarly use of subcutaneous MTX monotherapy vs. MTX oral or combination therapy significantly delays time to initiating biologics in early RAArthritis Rheumatol201668suppl 10 Available from: http://acrabstracts.org/abstract/early-use-of-subcutaneous-mtx-monotherapy-vs-mtx-oral-or-combination-therapy-significantly-delays-time-to-initiating-biologics-in-early-ra/Accessed November 18, 2016
   Google Scholar
• GalloGBrockFKerkmannUKolaBHuizingaTWEfficacy of etanercept in combination with methotrexate in moderate-to-severe rheumatoid arthritis is not dependent on methotrexate dosageRMD Open201621e00018627175292
   PubMedGoogle Scholar
• MandersSHMvan de LaarMAFJRongen-van DartelSAATapering and discontinuation of methotrexate in patients with RA treated with TNF inhibitors: data from the DREAM registryRMD Open20151e00014726535151
   PubMed Web of Science ®Google Scholar
• FleischmannRMCohenSBMorelandLWMethotrexate dosage reduction in patients with rheumatoid arthritis beginning therapy with infliximab: the Infliximab Rheumatoid Arthritis Methotrexate Tapering (iRAMT) trialCurr Med Res Opin20052181181119016083527
   PubMed Web of Science ®Google Scholar